NCT04040686View on ClinicalTrials.gov

HER2 Expression Detection in Breast Cancer Using 99mTc-NM-02

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 29, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

March 30, 2022

Conditions
Breast Cancer
Interventions
DRUG

Injection of 99mTc-NM-02

Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer

Trial Locations (1)

200080

Shanghai General Hospital, Shanghai

All Listed Sponsors
collaborator

NanoMab Technology (UK) Limited

INDUSTRY

lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT04040686 - HER2 Expression Detection in Breast Cancer Using 99mTc-NM-02 | Biotech Hunter | Biotech Hunter